VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection
出版年份 2023 全文链接
标题
VE303, a Defined Bacterial Consortium, for Prevention of Recurrent Clostridioides difficile Infection
作者
关键词
-
出版物
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 329, Issue 16, Pages 1356
出版商
American Medical Association (AMA)
发表日期
2023-04-15
DOI
10.1001/jama.2023.4314
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection
- (2022) Paul Feuerstadt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers
- (2022) Melissa Dsouza et al. Cell Host & Microbe
- Microbiome therapy for recurrent Clostridioides difficile
- (2022) Judith A Gilbert Lancet Microbe
- Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
- (2022) Sahil Khanna et al. DRUGS
- ACG Clinical Guidelines
- (2021) Colleen R. Kelly et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Tapered-Pulsed Fidaxomicin Regimen following Treatment in Patients with Multiple Clostridioides difficile Infection Recurrences
- (2021) Andrew M Skinner et al. CLINICAL INFECTIOUS DISEASES
- Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults
- (2021) Stuart Johnson et al. CLINICAL INFECTIOUS DISEASES
- European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults
- (2021) Joffrey van Prehn et al. CLINICAL MICROBIOLOGY AND INFECTION
- Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes
- (2020) Alice Y. Guh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Shiga toxin-producing E. coli transmission via fecal microbiota transplant
- (2020) Caroline Zellmer et al. CLINICAL INFECTIOUS DISEASES
- Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
- (2019) Zachariah DeFilipp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Translating microbiome futures
- (2018) Gaspar Taroncher-Oldenburg et al. NATURE BIOTECHNOLOGY
- Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection
- (2017) Mark H. Wilcox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adverse events in faecal microbiota transplant: a review of the literature
- (2016) M. Baxter et al. JOURNAL OF HOSPITAL INFECTION
- The Evolution of Urban C. difficile Infection (CDI): CDI in 2009–2011 Is Less Severe and has Better Outcomes Than CDI in 2006–2008
- (2014) Paul Feuerstadt et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Hospital-Acquired Clostridium difficile Infections
- (2014) Eric T. Lofgren et al. EPIDEMIOLOGY
- Role of the Intestinal Microbiota in Resistance to Colonization by Clostridium difficile
- (2014) Robert A. Britton et al. GASTROENTEROLOGY
- Clostridium difficile and the microbiota
- (2014) Anna M. Seekatz et al. JOURNAL OF CLINICAL INVESTIGATION
- Determinants of Clostridium difficile Infection Incidence Across Diverse United States Geographic Locations
- (2014) F. C. Lessa et al. Open Forum Infectious Diseases
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
- (2012) O. A. Cornely et al. CLINICAL INFECTIOUS DISEASES
- Can we identify patients at high risk of recurrent Clostridium difficile infection?
- (2012) C.P. Kelly CLINICAL MICROBIOLOGY AND INFECTION
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing
- (2008) Les Dethlefsen et al. PLOS BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started